Company: RGNT
Filing Date: 2025-02-12
Form Type: DRS/A
Source: 0001213900-25-012299
Chunk: 102

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-02-12
Form: DRS/A
Chunk 102
---
 $4.1 million and $1.4 million for the years ended December 31, 2023 and December 31, 2022, respectively.
As of June 30, 2024 and December 31, 2023, we had an accumulated deficit of $39.7 million and $46.9 million, respectively. We anticipate
that we will continue to incur significant losses for the foreseeable future as our operating expenses and capital expenditures increase
substantially due to our continued investment in our research and development activities and as we hire additional employees over the
coming years. Furthermore, upon closing of this offering, we expect to incur additional expenses associated with operating as a public
company on the Nasdaq, including significant legal, accounting, investor relations and other expenses.

For further information regarding
our business and operations, see “Business” below.

Components of Operating Results

Revenues

We have not recognized any
revenue to date, and we do not expect to generate revenue from the sale of products in the near future.

Research and Development Expenses

Research and development activities
are our primary focus. We do not believe that it is possible at this time to accurately project total expenses required for us to reach
the point at which we will be ready to out-license our technologies. Development timelines, the probability of success and development
costs can differ materially from expectations. In addition, we cannot forecast whether and when collaboration arrangements will be entered
into, if at all, and to what degree such arrangements would affect our development plans and capital requirements. We expect our research
and development expenses to increase over the next several years as our development program progresses. We would also expect to incur
increased research and development expenses if we were to identify and develop additional technologies.

Research and development expenses
include the following:

| ● | employee-related expenses, such as salaries and share-based compensation; |

| ● | expenses relating to outsourced and contracted services, such as consulting, research and advisory services; |

| ● | supply and development costs; |

| ● | expenses incurred in operating our small-scale equipment; and |

| ● | immaterial costs associated with regulatory compliance. |

We recognize research and
development expenses as we incur them.

<div align='center'>63</div>

General and Administrative Expenses

General and administrative
expenses consist primarily of personnel costs, facility costs and maintenance expenses, and external professional service costs, including
legal, accounting, audit, finance, business development, investor relations and human resource services